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Abstract
AR-12 has been evaluated in clinical trials as an anti-cancer agent but also has demonstrated host-
directed, broad-spectrum clearance of bacteria. We have previously shown that AR-12 has activity 
in vitro against Salmonella enterica serovar Typhimurium and Francisella species by inducing 
autophagy and other host immune pathways. AR-12 treatment of S. Typhimurium-infected mice 
resulted in a 10-fold reduction in bacterial load in the liver and spleen and an increased survival 
time. However, AR-12 treatment did not protect mice from death, likely due poor formulation. In 
the current study, AR-12 was encapsulated in a microparticulate carrier formulated from the novel 
degradable biopolymer acetalated dextran (Ace-DEX) and subsequently evaluated for its activity 
in human monocyte-derived macrophages (hMDMs). Our results show that hMDMs efficiently 
internalized Ace-DEX microparticles (MPs), and that encapsulation significantly reduced host cell 
cytotoxicity compared to unencapsulated AR-12. Efficient macrophage internalization of AR-12 
loaded MPs (AR-12/MPs) was further demonstrated by autophagosome formation that was 
comparable to free AR-12 and resulted in enhanced clearance of intracellular Salmonella. Taken 
together, these studies provide support that Ace-DEX encapsulated AR-12 may be a promising 
new therapeutic agent to control intracellular bacterial pathogens of macrophages by targeting 
delivery and reducing drug toxicity.
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1. Introduction
Salmonella is a Gram-negative facultative intracellular bacterial pathogen that is responsible 
for approximately 1.3 billion human infections annually (Coburn et al., 2007). Among the 
over 2500 serovars of S. enterica identified, Salmonella enterica serovar Typhi (S. Typhi), 
the etiologic agent of typhoid fever, is a human specific disease with an estimated 21 million 
new infections a year resulting in approximately 200,000 deaths annually worldwide 
(Crump et al., 2004). Once inside host cells, Salmonella utilizes various mechanisms to 
evade killing by macrophages. One such mechanism is the formation of Salmonella-
containing vacuoles (SCVs) where bacteria proliferate by exploiting cellular nutrition 
through an alteration in host cell vesicle trafficking, and by evading the phagocyte oxidase 
complex (Coburn et al., 2007). In parallel, the macrophage uses various innate immune 
mechanisms to defend against intracellular invasion of Salmonella including the formation 
of autophagosomes (Birmingham and Brumell, 2006; Birmingham et al., 2006). After 
escaping from damaged SCVs, bacteria have been shown within autophagosomes and are 
eliminated by the fusion of lysosomes with these vesicles (Birmingham and Brumell, 2006; 
Birmingham et al., 2006).
Not only is Salmonella evasive to clearance by the immune system, but the emergence of 
multi-drug resistant strains illustrates its ability to overcome common antibiotic therapies 
(Zaki and Karande, 2011). Although resistance is more common in non-typhoidal 
salmonellae, S. Typhi resistance to ceftriaxone has been documented as emerging in 
Bangladesh and Kuwait for up to 15 years (Afzal et al., 2013). Indeed, a recent study in 
Pakistan and India concludes that 73.7% (n=80), 56.2%, and 52.5% of bacterial isolates had 
developed resistance to sulfonamide, ampicillin, or streptomycin, respectively (Afzal et al., 
2013), with 58.7% of the overall isolates having multi-drug resistance. Resistant strains have 
also been observed in Kenya with resistance against cotrimoxazole in 66.7% (22 
individuals) of the S. Typhi clinical isolates (Onyango et al., 2008) and in the United States 
where sulfamethoxazole resistance was observed in 56% of food-borne S. Typhi isolates 
(Glynn et al., 2004). To better combat this evasive pathogen, host-cell directed therapy is an 
attractive option. Host-cell directed therapy has been developed to treat infection due to 
several pathogens (Collier et al., 2013) [e.g., Mycobacterium tuberculosis (Zumla et al., 
2013), viral diseases (Moore et al., 2013), malaria (Achtman et al., 2012)] in an effort to 
lessen the pathogens’ ability to evade clearance by the immune system as well as to limit the 
pathogens’ development of resistance.
Here we apply host-targeted AR-12 to combat S. Typhi within infected macrophages. AR-12 
is a small molecule derived from a COX-2 inhibitor, but which now lacks COX-2 activity. It 
has been shown to suppress tumor cell viability through multiple mechanisms including 
activation of endoplasmic reticulum stress, inhibition of PDK-1/Akt signaling and the 
induction of autophagy (Gao et al., 2008; Kucab et al., 2005; Park et al., 2008). Moreover, it 
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has received Food and Drug Administration Investigational New Drug (FDA-IND) approval 
and completed clinical trials for cancer treatment (#NCT00978523). With respect to 
bacterial infection, unencapsulated (free) AR-12 has displayed broad-spectrum activity in 
vitro against Salmonella enterica Typhimurium (S. Typhimurium) and Francisella 
tularensis (Chiu et al., 2009a; Chiu et al., 2009b) wherein bacterial burdens were 
significantly reduced in the host macrophage, in vitro. Our previous studies showed that free 
AR-12 is capable of enhancing clearance of S. Typhimurium in mouse cells via increased 
autophagy and other host immune activating pathways. Induction of autophagy by 
pharmacological agents has been shown to reduce the survival of various intracellular 
pathogens (Abdulrahman et al., 2011; Amer and Swanson, 2002; Amer and Swanson, 2005; 
Birmingham and Brumell, 2006; Birmingham et al., 2006; Biswas et al., 2008; Campbell 
and Spector, 2012; Chiu et al., 2009a; Gutierrez et al., 2004; Nakagawa et al., 2004). In vivo 
AR-12 treatment of S. Typhimurium infection resulted in a 10-fold reduction in bacterial 
load in the liver and spleen as well as a significant increase in survival time of infected mice 
(Chiu et al., 2009a). Despite these promising results, AR-12 treatment did not prevent mice 
lethality, likely due to the inability to achieve a sufficient in vivo concentration because of 
the hydrophobicity of this drug.
To increase the intracellular concentration of AR-12, we have encapsulated it into a 
microparticulate carrier comprised of the novel biodegradable polymer acetalated dextran 
(Ace-DEX) (Bachelder et al., 2008a; Broaders et al., 2009a; Kauffman et al., 2012a). Ace-
DEX is unique among other commonly used biodegradable polymers, including polyesters 
such as poly(lactic-co-glycolic acid) (PLGA) and polycaprolactone (PCL), because it creates 
pH neutral degradation products of dextran and extremely low levels of both ethanol and 
acetone, a metabolic product. Moreover, it has tunable degradation kinetics that can range 
from hours to days (Broaders et al., 2009a) due to the polymer’s acid-sensitivity which 
offers advantages for exposure to the bacterium in a relatively acidic phagosomal 
environment (Bachelder et al., 2008a). By encapsulating AR-12 in an Ace-DEX 
microparticle (MP), we can overcome the poor water solubility of the drug and facilitate 
macrophage passive targeting since non-phagocytic cells are not able to efficiently 
internalize particles larger than 100nm (Foged et al., 2005; Hirota et al., 2007). Thus, 
encapsulation of AR-12 should enhance its delivery by providing a triggered release of the 
drug intracellularly within the phagosome.
Here, we encapsulated AR-12 within Ace-DEX MPs and evaluated these particles for drug 
loading, size and shape. Additionally, we assessed the uptake of fluorescently labeled Ace-
DEX MPs and determined the cytotoxicity and drug concentration of AR-12-loaded Ace-
DEX MPs (AR-12/MPs) in macrophages. To evaluate the encapsulated drug’s effect, the 
ability of AR-12/MPs to modulate autophagy and clearance of S. Typhimurium was 
measured. Taken together, the studies described herein provide support that Ace-DEX 
encapsulated AR-12 may be a promising new therapeutic agent to control intracellular 
bacterial pathogens of macrophages.
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2. Materials and Methods
2.1. Reagents and antibodies
AR-12 was provided by Arno Therapeutics, Inc. (Flemington, NJ). Lipopolysaccharide 
(LPS) and IFN-γ were purchased from EMD Millipore (Billerica, MA). The following 
antibodies were used in this study: anti-LC3 antibody (Abcam, Cambridge, MA, USA), anti-
S. Typhi antibody (Biodesign, Lake Forest, CA), Alexa Red-conjugated goat anti-mouse 
IgG, and Alexa Green goat anti-rabbit IgG (Invitrogen, Carlsbad, CA). All chemicals, except 
where indicated, were purchased from Sigma (St. Louis, MO) and used as purchased.
2.2. Fabrication of Ace-DEX
Acetalated dextran (Ace-DEX) was reacted as previously outlined (Kauffman et al., 2012a). 
In brief, lyophilized 71k dextran was reacted in acidic and anhydrous conditions in the 
presence of 2-ethoxypropene (Waterstone, Carmel, IN). The reaction was quenched with the 
addition of triethylamine (TEA) and purified via filtration. The end product was resuspended 
in water made basic (pH ~9) through the addition of TEA, lyophilized, washed in ethanol, 
re-lyophilized and weighed to get an overall yield of 94–98%. The cyclic acetal coverage 
was characterized via NMR (Broaders et al., 2009a) and determined to be 50–56% for all 
polymers used in this study.
2.3. Encapsulation of AR-12 in Ace-DEX MPs
The production of MPs was performed as described in our previous publications (Broaders 
et al., 2009b; Kauffman et al., 2012b) with the addition that dishes and glassware were 
soaked in 0.5 M sodium hydroxide overnight, rinsed with isopropanol and dried prior to use. 
Two mg of the AR-12 was added to 100 mg of Ace-DEX (2% wt/wt loading), dissolved in 
dichloromethane (DCM) and 3% wt/wt polyvinyl alcohol (PVA) in phosphate buffer saline 
(PBS, pH 7.4) was added to the solution. The mixture was sonicated using a Misonix 
Ultrasonic Liquid Processor (Farmingdale, NY; 60 W, duty cycle 50%) while chilled in an 
ice bath. The emulsion was then poured into a 0.3% PVA solution in PBS and stirred for 2h 
to evaporate the organic solvent. The suspension was filtered using a sterile MidiKros 
tangential flow filtration system (Spectruam Labs, Rancho Dominguez, CA) to remove un-
encapsulated drug and PVA. The particles were then collected and lyophilized. For 
fluorescently loaded particles, 1′-Dioctadecyl-3,3,3′,3′-tetramethylindocarbocyanine 
perchlorate MPs (DTP) was loaded at 1% weight loading in the same manner outlined 
above. Also, the same procedure was used to fabricate blank particles without adding drug. 
The AR-12 loaded particles (AR-12/MPs) and blank particles were confirmed to have LPS 
levels below detection limits, prior to use as assessed using a ToxinSensor ™ Chromogenic 
LAL Endotoxin Assay Kit (GenScript USA Inc, Piscataway, NJ).
2.4. Quantification of AR-12 in Microparticles and Macrophages
To quantify the amount of AR-12 in Ace-DEX MPs, AR-12/MPs were prepared in a 1 gL-1 
solution of dimethyl sulfoxide (DMSO). A standard curve of unencapsulated AR-12 in 
DMSO was then prepared in a solvent resistant 96-well plate (Polypropylene; Thermo 
Fisher Scientific, Waltham, MA) with triplicate samples of broken-down, previously 
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encapsulated AR-12. These samples were then read in a plate reader at λex 280nm/λem 
380nm and used to calculate the amount of drug encapsulated. The encapsulation efficacy 
was then determined as the amount of drug encapsulated divided by the amount of drug 
loaded (the theoretical drug loading).
The amount of AR-12 in macrophages was also quantified. RAW 264.7 macrophages 
(5×104 cells/well) were left to adhere 2–3 hours in a 96-well plate with Thermo Scientific 
HyClone DMEM (Dulbecco's Modified Eagle's Medium)/high glucose with 5% Fetal 
Bovine Serum and 1% penicillin/streptomycin. Cells were then cultured for 24 hours with 
either free AR-12 in DMSO or AR-12/MPs. After culturing, cells were washed twice with 
chilled PBS, lysed with the addition of 200 µl of the mobile phase solution (by volume) and 
centrifuged at 4000 rpm for 10 minutes. The mobile phase solution consisted of acetonitrile 
(55%), acetic acid (0.5%), Triton X-100 (0.1%), and ddH2O (44.4%). Lysates from each 
well were transferred to an Amicon Ultra Centrifugal Filter (Millipore). The filtrate from 
each tube was chilled overnight at 4°C and quantification of AR-12 was determined by high-
performance liquid chromatography (HPLC). AR-12 concentration was determined using an 
Agilent 1100 series HPLC with a 1260 diode array (Santa Clara, CA). Samples were run 
through a ZORBX Eclipse XDB-C8 4.6 mm × 150 mm (Agilent), pore size 5 µm column, 
with a C8-guard column and passed through the column at a flow rate of 1 ml/min in the 
mobile phase. AR-12 was detected at a wavelength of 267 nm with a retention time of 2.9 
minutes. Sample peaks were compared to a standard curve and analyzed using Agilent 
Chemstation software.
2.5. Characterization of Microparticle Size
Dynamic light scattering (DLS) samples were prepared in basic water (pH 9.0) and diluted 
to reduce the average count rate to ~100 kilocounts/min when analyzed with a BI-200SM 
DLS system (Brookhaven Instruments, Holtsville, NY). The reading was performed using a 
laser wavelength of 633nm, pinhole setting of 200 µm and detector angle of 90°. The 
average of five readings was taken and reported.
Particle size and morphology was obtained using a NOCA Nano SEM 400 (Field Emission, 
Inc., Hillsboro OR). Particles were suspended at a concentration of 10gL−1 in basic water 
(pH 9.0) and pipetted onto an aluminum pin stub specimen mount (Ted Pella; Redding, CA) 
and allowed to air dry at room temperature. Using a Sputter Coater 108 (Cressington 
Scientific Instruments, Watford, England), the samples were coated with a layer of gold-
palladium alloy for two minutes and images were acquired with the SEM.
2.6. Isolation of human monocyte-derived macrophage (hMDMs)
Human monocyte-derived macrophages (hMDMs) were isolated from human blood via 
venipuncture (Schlesinger et al., 1990) from healthy donors following protocols approved by 
the Ohio State University Institutional Review Board. Written informed consent was 
provided by study participants. Briefly, peripheral blood mononuclear cells (PBMCs) were 
isolated from heparinized blood over a Ficoll cushion (GE Heathcare Bio-Science, 
Piscataway, NJ). PBMCs were then cultured in sterile screw-cap Teflon wells in RPMI 1640 
plus L-glutamine (Gibco-Life Technologies, Grand Island, NY) with 20% autologous 
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human serum at 37°C in a humidified incubator containing 5% CO2 for 5 days. PBMCs 
were then recovered from Teflon wells by chilling them on ice, re-suspending the cells in 
RPMI 1640 with 10% autologous serum, and allowing them to attach in 6-well or 24-well 
tissue culture plates for 2–3h at 37°C in a humidified incubator containing 5% CO2. 
Lymphocytes were then washed away leaving hMDM monolayers at a density of 
approximately 2.0×105 cells/well for 24-well plates or 8.0×105 cells/well for 6-well plates 
for S. Typhi infection or for collection of cell lysates, respectively.
2.7. Bacterial cultures and analysis of bacterial growth in hMDMs
Wild-type S. Typhi TY2, a gift from Dr. Carolyn Hardegree (FDA), was cultured in Luria-
Bertani (LB) broth (Difco, Detroit, MI) at 37°C. Analysis of bacterial growth in hMDMs 
was described previously (Chiu et al., 2009a). Briefly, overnight cultures of S. Typhi were 
prepared for infection of hMDMs by sub-culture (1:50) in fresh LB broth and incubated for 
4h at 37°C. Bacteria were then collected by centrifugation at 3,000g for 10 min and 
suspended in phosphate buffer saline (PBS) to an optical density of 0.6 at 600nm which was 
equivalent to 5×108 CFUmL−1. hMDMs were infected with S. Typhi at a multiplicity of 
infection (MOI) of 20 in the presence of 2% autologous serum in RPMI 1640 (Gibco-Life 
Technologies). Two hours after infection, extra-cellular bacteria were removed by addition 
of 100µgmL-1 gentamicin to the culture medium for 1h and then the cell layer was 
thoroughly washed three times with pre-warmed RPMI 1640. The infected hMDMs were 
then treated with different concentrations of free AR-12 or AR-12/MPs in fresh culture 
medium containing 2% autologous serum. Gentamicin was also added at 10µgmL−1 to 
eliminate potential re-infection by extracellular bacteria. At different time points, the 
infected cells were lysed with 0.1% Triton X-100 (Calbiochem, San Diego, CA) in PBS for 
15 min. The cell lysates were then serially diluted with PBS and spread on LB agar plates. 
The surviving intracellular bacteria were determined by enumerating CFU after 24h 
incubation at 37°C.
2.8. Cytotoxicity assay
The effects of free AR-12 and AR-12/MPs on hMDM viability were assessed by using a 
lactate dehydrogenase (LDH) assay (Roche Applied Science, Indianapolis, IN). Prior to the 
experiment, hMDM cells were seeded into 24-well plates at 2×105 cells/well (3 wells per 
test group) with RPMI 1640 supplemented with 20% autologous serum. The medium from 
each well was removed and replaced with fresh 2% autologous serum in RPMI 1640 
containing different concentrations of free AR-12 dissolved in dimethyl sulfoxide (DMSO; 
final concentration of 0.1%), AR-12/MPs, blank MPs or DMSO vehicle control. The 
positive control received 0.1% Triton X-100 at the time of harvesting supernatants. After 
72h of treatment, supernatants were collected, centrifuged to remove cells, and subjected to 
the LDH assay (as per manufacturer’s instructions). Absorbance at 570 nm was determined 
via a plate reader and the cytotoxicity was calculated as a percentage compared to the 
positive control treated cells.
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For visualizing the internalization of MPs into hMDMs, DTP (λex 550 nm; λem 567 nm) 
Ace-DEX microparticles were prepared (DTP/MPs). hMDMs were cultured with DTP/MPs 
at a MP concentration equivalent to 2.5µM AR-12. At different time points, cells were 
washed, fixed and examined for DTP/MP internalization into hMDMs. The percentage of 
DTP/MP positive hMDMs was determined by dividing DTP/MP positive cells by the total 
number of hMDMs randomly counted from at least three epifluorescence microscope 
viewing fields (≥ 300cells/test group).
Epifluorescence microscopy was used to visualize intracellular S. Typhi, autophagosomes 
and microparticles. The ability of AR-12/MPs to induce autophagosomes was examined 
using a Cyto-ID® Autophagy Detection kit (Enzo Life Science, NY). Briefly, 2×105 
hMDMs on coverslips were treated with either 1.25µM free AR-12 in DMSO or AR-12/MPs 
for 18h, the cells were then washed three times with warm PBS and then one time with 1× 
assay buffer. The autophagosomes and nuclei were labeled with Cyto-ID® Autophagy 
Detection and Hoechst 33342 Nuclear stain, respectively, at 37°C in 5% CO2 incubator. 
After a 30 min incubation, the cells were washed with 1× assay buffer and fixed with 4% 
formaldehyde for 20 min at room temperature. The stained cells were visualized using 
epifluorescence microscopy with a FITC filter (λex 480 nm, λem 530nm) and the nuclear 
Hoechst 33342 with a DAPI filter (λex 340nm, λem 480nm).
The co-localization of intracellular S. Typhi with autophagosomes was examined as 
described previously (Chiu et al., 2009a) with minor modification. Briefly, hMDMs were 
infected with S. Typhi as described (MOI = 20) for 2h. After removal of extracellular 
bacteria, the infected cells were treated with 1.25µM AR-12/MPs. At different time points, 
the infected cells were washed three times with PBS, fixed with 4% paraformaldehyde in 
PBS for 20 min, permeabilized with ice-cold methanol for 10 sec and blocked with 3% 
bovine serum albumin (BSA) in PBS overnight at 4°C. After three washes with PBS, the 
cells were incubated with a mixture of primary antibodies [1:100 mouse S. Typhi antibody 
and 1:100 rabbit LC3 antibody] in 5% goat serum in PBS. After a 2h incubation at room 
temperature, the cells were blocked with 3% BSA for 1h and incubated with a mixture of 
fluorescently-labeled secondary antibodies of goat anti-rabbit Fluor 488 and goat anti-mouse 
Fluor 546 (Invitrogen, Carlsbad). Cells were washed three times with PBS after a 2h 
incubation and macrophage nuclei were stained with DAPI.
To examine if S. Typhi co-localizes with AR-12/MPs, hMDMs were infected with GFP-
expressing S. Typhi (MOI = 100) for 1h and then treated with AR-12/MPs at an MP 
concentration equivalent to 2.5µM AR-12/MPs. At different time points, cells were washed, 
fixed with 4% paraformaldehyde and macrophage nuclei were stained with DAPI.
2.10. Immunoblotting
Western blots were performed to examine the autophagy protein LC3 and its derivative form 
LC3-II as previously described (Chiu et al., 2009a; Chiu et al., 2009b). Briefly, after 
treatment with free AR-12 or AR-12/MPs, cells were washed with ice-cold PBS, lysed and 
incubated on ice for 10 min. After centrifugation at 14,000×g for 10 min, equivalent 
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amounts of lysate supernatant were mixed with 4× Laemmli buffer and heated to 95°C for 5 
min. 20µg protein equivalents were resolved by SDS-PAGE (12%) and transferred onto a 
0.2µm nitrocellulose membrane. The membrane was blocked with 5% skim milk in Tris-
buffered saline (TBS) for 1h and rinsed with 0.5%Tween-20 in TBS (TBST), incubated 
overnight at 4°C with rabbit anti-LC3 antibody (1:1000) in 5% skim milk dissolved in 
TBST, washed six times with TBST and incubated with HRP-conjugated goat anti-IgG 
secondary antibody (1:2000) in 5% skim milk/TBST for 1h. After six washes with TBST, 
the immune-positive bands were visualized by enhanced chemiluminescence (GE 
Amersham, Piscataway, NJ) on X-ray film.
2.11. Statistical analysis
Data are presented as mean ± standard deviation (SD). p-values were calculated using one-
way ANOVA for multiple comparisons and adjusted with Bonferroni’s correction or using a 
non-paired Student’s t test where two group means were 
compared; *p<0.05; **p<0.01; ***p<0.001; NS, not significant. Statistical analysis was 
performed using GraphPad Prism 5.
3. Results
3.1. Encapsulation of AR-12 into Ace-DEX microparticles
To address the proposed enhanced clearance of intracellular Salmonella by encapsulation of 
the autophagy inducer AR-12, MPs were produced to contain the drug as cargo. Fig. 1 
displays a representative scanning electron micrograph of AR-12-loaded Ace-DEX MPs 
(AR-12/MPs), illustrating that the particles are spherical in nature. As the DLS and SEM 
micrographs indicate, the particles are polydispersed in nature with a size of 255 ± 45 nm 
(n=5). The encapsulation efficiency is 44.7% and the drug loading is 8.95 µg AR-12/mg 
Ace-DEX.
3.2. Cytotoxicity of AR-12 in Ace-DEX microparticles in macrophages
From a clinical perspective, treatment of infectious diseases caused by intracellular 
pathogens may require prolonged treatment regimens and the ability for agents to access 
intracellular sites with limited toxicity. Thus to examine cytotoxicity, hMDMs, which serve 
as the primary target in vivo for S. Typhi, were treated with empty Ace-DEX particles, free 
AR-12 or AR-12/MPs for 72h. LDH release was monitored in the supernatants as an 
indicator of cell toxicity. For each concentration, the blank particle group represents the 
same mass of particles that corresponds to the given mass of AR-12/MPs for that particular 
AR-12 concentration. To equalize AR-12 concentrations between free AR-12 and AR-12/
MPs, the amount of AR-12 from AR-12/MPs was determined using the known AR-12 
encapsulation efficiency. The percentage of cytotoxicity is significantly higher (p<0.001) in 
the free AR-12 group compared to the AR-12/MPs or MP group at the 5µM and 10µM 
concentrations at the 72h time point (Fig. 2). The empty MP groups at any of the 
concentrations exerted minimal or no toxicity with respect to the cells only control. These 
results provide strong evidence that encapsulation of AR-12 into Ace-DEX MPs reduces 
toxicity of the drug for human macrophages.
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3.3. Internalization of AR-12/MPs into macrophages
Given the reduction in cytotoxicity for hMDMs observed in Fig. 2, we addressed the formal 
possibility that AR-12/MPs were poorly internalized into macrophages by examining the 
ability of AR-12/MPs to be phagocytosed by macrophages. 1,1′-Dioctadecyl-3,3,3′,3′- 
tetramethylindocarbocyanine perchlorate (DTP; λex 550 nm; λem 567 nm) was encapsulated 
into Ace-DEX MPs (DTP/MPs) and hMDMs were cultured with DTP/MPs at a MP 
concentration equivalent to 2.5µM AR-12. Internalization of DTP/MPs was examined by 
epifluorescence microscopy at different time points. As shown in Fig. 3, DTP/MPs were 
efficiently internalized into hMDMs. By the 60 min time point, 97.8±2.62% of the hMDMs 
had internalized MPs. We next compared the intracellular concentration of AR-12 between 
free AR-12- and AR-12/MP-treated RAW 264.7 cells. The drug concentration was measured 
in cell lysates at 24h after treatment using HPLC. As shown in Fig. 4, encapsulation of 
AR-12 increased cell loading of the drug, reaching peak intracellular concentrations at 10 
µM initial encapsulated AR-12, while free AR-12 plateaued at 5 µM initial loading, where 
significant cell death occurred with the unencapsulated drug (Fig 2). Thus, encapsulation of 
AR-12 not only reduces cell cytotoxicity but also increases the intracellular drug 
concentration.
3.4. AR-12/MP-induced autophagosome formation is comparable to free AR-12
Ace-DEX MP encapsulated AR-12 is efficiently internalized by hMDMs, resulting in an 
increased intracellular concentration of the drug. Therefore the ability of AR-12/MPs to 
induce autophagosome formation in hMDMs was next assessed and compared with that of 
free AR-12. hMDMs were exposed to 1.25µM of either free AR-12 or AR-12/MPs for 18h 
and evaluated for evidence of autophagy by microscopy and Western blot analysis. 
Autophagosomes in the cytosol were labeled using a Cyto-ID Autophagy Detection Kit and 
visualized using epifluorescence microscopy. As shown in Fig. 5A, AR-12/MPs induced 
autophagosome formation comparable to free AR-12 in hMDMs as evidenced by 
characteristic speck formation (green). Additionally, during autophagy the cytoplasmic 
protein microtubule-associated protein light chain 3-I (LC3-I) is cleaved and recruited to the 
autophagosomes where LC3-II, a specific autophagosome marker, is generated via site-
specific lipidation (Deretic et al., 2013). As shown in Fig. 5B, immunoblotting of the LC3-II 
protein in lysates from AR-12/MP-treated macrophages showed an increase in LC3-II levels 
comparable to that in free AR-12-treated macrophages. Together, the results indicate that 
AR-12/MPs are capable of inducing autophagy in hMDMs similar to free AR-12.
3.5. AR-12/MPs reduce S. Typhi growth in hMDMs
Our previous studies demonstrated that free AR-12 inhibited the growth of intracellular 
bacteria in macrophages via induction of autophagy and other immune mechanisms (Chiu et 
al., 2009a; Chiu et al., 2009b). To examine whether AR-12/MPs are also capable of 
inhibiting S. Typhi growth in macrophages, hMDMs were infected with S. Typhi (MOI = 
20) for 2h, washed and treated with different concentrations of free AR-12 or AR-12/MPs. 
The intracellular survival of S. Typhi in hMDMs was determined by CFUs of cell lysates. 
We first determined the growth curve of S. Typhi in hMDMs in the presence of 20µM 
AR-12/MPs and found that AR-12/MPs inhibit bacterial growth in a time-dependent 
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fashion. The maximal growth inhibition was obtained at 22h post treatment compared to the 
vehicle control (Fig. 6A). We next compared bacterial growth inhibition by free AR-12 and 
AR-12/MPs at 22h post treatment. As shown in Fig. 6B, free AR-12 had a stronger 
inhibitory effect on S. Typhi growth in hMDMs. However, like free AR-12, AR-12/MPs 
displayed a dose-dependent effect consistent with the specific activity of AR-12. It is 
possible that encapsulation makes the effect entirely related to internal cellular drug action 
like autophagy whereas free AR-12 has additive effects at the cost of toxicity.
3.6. AR-12/MPs do not exert direct antimicrobial activity towards S. Typhi
AR-12 may exert direct antimicrobial activity against S. Typhi in macrophages in addition to 
its host-directed effects. Previous studies have shown that free AR-12 does not have direct 
antimicrobial activity against Salmonella serovar Typhimurium (Chiu et al., 2009a). 
Consistent with the previous findings, free AR-12 concentrations as high as 10µM did not 
exhibit direct antimicrobial activity against S. Typhi over 24h (Fig. 7A). Additionally, we 
examined the potential co-localization of Salmonella with MPs inside the macrophages. 
Green fluorescent protein (GFP)-expressing S. Typhi was used to infect hMDMs for 1h 
(MOI= 100). The infected macrophages were then cultured with 2.5 µM DTP-labeled MPs 
at a concentration equivalent to 2.5µM of AR-12. GFP-expressing S. Typhi and DTP-labeled 
MPs were visualized using epifluorescence microscopy. As shown in Fig. 7B, we did not 
observe co-localization of GFP-expressing S. Typhi and DTP-labeled MPs. This finding, 
together with the lack of direct killing in vitro, suggests that AR-12 released from MPs 
intracellularly does not exert direct killing of S. Typhi.
3.7. Co-localization of S. Typhi with autophagosomes induced by AR-12/MPs
Because AR-12/MPs are also capable of inducing autophagy and inhibiting S. Typhi 
intracellular growth, we assessed the effects of AR-12/MPs on the co-localization of S. 
Typhi with autophagosomes in the infected hMDMs using epifluorescence microscopy. The 
results showed that treatment of the infected hMDMs with 1.25 µM AR-12/MPs for 6h 
resulted in approximately 50% bacteria co-localized with LC3-positive puncta compared to 
approximately 12% in the cells treated vehicle alone (Fig. 8A and C). Eighteen hours after 
AR-12/MP treatment, extensive co-localization of bacteria/bacterial debris with LC3-
positive puncta was observed in all infected hMDMs (Fig. 8B and C).
4. Discussion
The incidence of Salmonella infections and the rapid emergence of multidrug resistant S. 
Typhi (Parry et al., 2002) highlight the important worldwide threat of this pathogen and the 
need for new approaches to therapeutic intervention. Activation of host defense as well as 
targeting host factors modulated by microbes are emerging approaches to control 
intracellular pathogens (Finlay and Hancock, 2004; Schwegmann and Brombacher, 2008). 
The induction of autophagy is known to result in the elimination of intracellular pathogens, 
and AR-12 is a pharmacological agent capable of inducing autophagy in various cell types 
(Chiu et al., 2009a; Chiu et al., 2009b) where it inhibits intracellular bacterial growth within 
infected macrophages (Chiu et al., 2009a; Chiu et al., 2009b).
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While our previous work showed that AR-12 helped to clear bacteria from macrophages, it 
did not protect mice from lethality, possibly due to limited drug availability as a result of the 
drug’s hydrophobicity, a situation that can also promote drug resistance. To overcome the 
solubility issue and to increase delivery, we have encapsulated AR-12 in degradable 
acetalated dextran (Ace-DEX) microparticles that target phagocytes. The size of the MPs, as 
presented in Figure 1, is approximately 255 nm in diameter. For parenteral administration of 
MPs targeting macrophages, the ideal size is between 100–1,000nm. Particles less than 100 
nm (Foged et al., 2005; Hirota et al., 2007) are not efficiently internalized by macrophages 
and larger particles (1 −2 µm) are predominately transported by dendritic cells from the 
injection site to the lymph node (Manolova et al., 2008). Not only have we formulated MPs 
of a size ideal for delivering compounds to target host cells, but we have encapsulated the 
above mentioned novel, FDA-IND-approved small molecule therapeutics, AR-12. AR-12 
was encapsulated at a modest efficiency of 44.7% with a 2% initial weight loading. The loss 
of drug in the emulsion process is likely due to its partitioning into the aqueous phase. 
Overall, we have formulated particles that are approximately 9% AR-12 per polymer.
Use of encapsulated AR-12 for the delivery of drug to macrophages results in a significant 
decrease in drug cytotoxicity (Fig. 2) and an increase in intracellular drug concentration 
above what can be achieved with unencapsulated drug (Fig. 4). While this may appear 
paradoxical (MPs aid intracellular loading of the drug but still result in less cytotoxicity), it 
is likely that encapsulation reduces potential AR-12 interactions with non-specific targets at 
the cell surface or interior. The high amount of drug loading is not surprising since MPs are 
efficiently phagocytosed by hMDMs with nearly all of the macrophages containing MPs 
after 60 min (Fig. 3). Efficient uptake of MPs by macrophages was also observed with 
PLGA MPs of similar size to the Ac-DEX MPs reported here. Mathaes et al. report an 
approximately 70-times greater amount of fluorescence compared to media control, as 
determined by flow cytometry, when J774.A1 macrophages were cultured with FITC-PLGA 
MPs (Mathaes et al., 2014). This high amount of particle uptake also translates to a high 
amount of drug loading (Fig. 4) with the MP formulation resulting in increased loading 
compared to unencapsulated drug. The effects of high intracellular drug loading with Ace-
DEX MPs has been observed previously with small molecule drugs (Bachelder et al., 2010; 
Peine et al., 2013), wherein a drug dose sparing is observed. Dose sparing was also observed 
in PLGA as part of the Peine et al. study when comparing the cytokine response of 
macrophages treated with PLGA and Ac-DEX MPs encapsulating Poly I:C. However, the 
observed production of most inflammatory cytokines was greater for the faster degrading 
Ac-DEX MPs encapsulating Poly I:C than for the PLGA MPs (Peine et al., 2013). The 
increased activity of the Ac-DEX MPs indicates that the dose sparing and diminished 
toxicity are likely an effect of the acid-sensitivity of Ace-DEX. Ace-DEX particles undergo 
tunable burst release in acidic conditions but have slower, tunable release at neutral pHs 
(Bachelder et al., 2008b). Thus, once engulfed by phagocytic cells, the pH sensitive Ace-
DEX particles allow the burst release of their drug payload in the phagosomes thus 
maximizing the amount of drug released in the phagosomes while limiting release 
systematically. These characteristics of Ace-DEX make it a more desirable vehicle for the 
delivery of drugs such as AR-12 into phagocytes than other available materials.
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We found that AR-12/MPs induced at least equal levels of autophagy compared to free 
AR-12 (Fig. 5A and B). Based on a literature search, this paper is the first of its kind to 
encapsulate an autophagy agent in polymeric microparticles for antibacterial action. 
Autophagy inhibitors have been encapsulated as cancer chemotherapeutics (Zhang et al., 
2014), and tolerance (Kauffman et al., 2012b) but this area has not by and large been 
explored for the treatment of phagocytes to kill resident bacterial pathogens. Also, PLGA 
particles of similar size have been shown to increase autophagy (Halamoda Kenzaoui et al., 
2012), although this could be due to LPS or other endotoxin contamination since TLR 
agonists have been shown to increase autophagy (Collier et al., 2013). We did not observe 
that Ac-DEX blank particles significantly increased autophagy (Fig 5). Furthermore, 
addition of AR-12/MPs resulted in growth inhibition of S. Typhi in hMDMs in a dose- and 
time-dependent manner, with the most marked inhibition at 22h post treatment (Fig. 6A and 
B) with 94% co-localization of the bacteria and autophagy vacuoles. No direct antimicrobial 
activity of AR-12 for S. Typhi was observed. AR-12 has been shown to induce autophagy 
via inhibition of Akt-1, an upstream regulator of mTOR (Chiu et al., 2009a). The host cell 
kinase Akt 1 is important for the intracellular survival of bacterial pathogens via multiple 
mechanisms and inhibition of this kinase impairs the growth of S. Typhimurium and M. 
tuberculosis (Kuijl et al., 2007) in host macrophages. It is notable that our efforts to induce 
autophagy in hMDMs using rapamycin or starvation were unsuccessful, suggesting 
differences in the sensitivity to conventional autophagy inducing agents between hMDMs 
and murine macrophages due to unknown mechanisms (data not shown). Although our 
current study clearly indicates an effect of AR-12 on S. Typhi clearance in hMDMs, our 
earlier study showed that free AR-12 displays a biphasic effect on intracellular growth of S. 
Typhimurium in macrophages (Chiu et al., 2009a) that is dependent on both autophagy and 
non-autophagic mechanisms (Chiu et al., 2009a; Chiu et al., 2009b). We did not observe a 
biphasic effect on inhibition of intracellular growth of S. Typhi in hMDMs, perhaps due to 
the controlled and intracellular release of drug from AR-12/MPs. Nonetheless, our studies 
indicate that AR-12/MPs are potent autophagy activators in hMDMs. In many studies, 
autophagy-mediated bacterial killing has been defined as the co-localization of bacteria and 
LC3, but it is obvious that LC3 can decorate membranous compartments other than 
autophagosomes including phagosomes. Our study demonstrated that AR-12/MPs increased 
conversion of LC3-I to LC3-II and co-localization of S. Typhi with LC3 (Fig. 5A and B and 
Fig. 8A and B), reinforcing that inhibition of intracellular bacterial growth was likely as a 
result of inducing autophagy.
5. Conclusion
Encapsulation of AR-12 in Ace-DEX particles (AR-12/MPs) facilitates the passive targeting 
of macrophages and improves AR-12 delivery to hMDMs. While increasing intracellular 
drug concentration, AR-12/MPs significantly reduced host cell cytotoxicity compared to free 
AR-12. The improvement of drug delivery by encapsulation in vitro was further 
demonstrated by its ability to induce robust autophagosome formation and the enhanced 
clearance of S. Typhi in infected hMDMs. Taken together, these studies provide support that 
Ace-DEX encapsulated AR-12 may be a promising new therapeutic agent to control the 
intracellular growth of bacterial pathogens.
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DMSO Dimethyl sulfoxide
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FDA Food and Drug Administration
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Representative scanning electron micrograph of Ace-DEX microparticles (MPs) 
encapsulating AR-12, scale bar represents 5 µM.
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Cytotoxicity of human monocyte-derived macrophages (hMDMs) cultured in the absence or 
presence of AR-12 for 72h. AR-12 = un-encapsulated drug, AR-12/MPs = encapsulated 
AR-12, and MPs = empty Ace-DEX microparticles. Cytotoxicity is presented as relative 
LDH release compared to positive control (0.2% Triton X-100). Data are presented as 
average ± SD (***P ≤ 0.001).
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Efficient internalization of 1,1′-Dioctadecyl-3,3,3′,3′-tetramethylindocarbocyanine 
perchlorate MPs (DTP/MPs) into hMDMs at a concentration of 2.5 µM AR-12. The cells 
were visualized using epifluorescence microscopy. Nuclei were stained with DAPI (blue). 
Green represents DTP/MPs. The results are representative of two experiments.
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Intracellular drug concentration in RAW 264.7 macrophages cultured with un-encapsulated 
(Free) or Ace-DEX microparticles encapsulating AR-12 (AR-12/MPs). Drug concentration 
was measured in cell lysates by HPLC. The decrease in cell concentration at 10 µM is due to 
cytotoxicity, which is high above 5 µM of free drug.
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AR-12/MP-induced autophagosome formation in hMDMs is greater than or equal to free 
AR-12. (A) Nuclei were stained with DAPI (blue) and autophagosomes were labeled with a 
cationic amphiphilic tracer dye (green). The results shown are representative of two 
experiments. (B) Western blot using anti-LC3 antibody. LC3 cleavage was induced by 
AR-12/MPs; (1) Medium control; (2) Equivalent amount of blank MPs; (3) 1.25µM free 
AR-12; (4) 1.25 µM AR-12/MPs; (5) 100nM LPS and 100nM IFN-γ as a positive control. 
The results are representative of five experiments.
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Inhibition of intracellular growth of S. Typhi in macrophages by AR-12/MPs. (A) Time-
dependent effects of 20µM AR-12/MPs on intracellular growth of S. Typhi. hMDMs were 
incubated with S. Typhi for 2h. After the removal of extracellular bacteria, the infected cells 
were treated with 20µM AR-12/MPs. The bacterial load (CFU) was determined by plating 
cell lysates. (B) AR-12/MPs retained ability to enhance the clearance of S. Typhi by 
hMDMs. Infected hMDMs were treated with different doses of unencapsulated AR-12 or 
AR-12/MPs. The bacterial load (CFU) was determined at 22h post treatment. AR-12 = un-
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encapsulated drug, AR-12/MPs = encapsulated AR-12, and AP = empty Ace-DEX 
microparticles. The data are presented as average ± SD (P ≤ 0.05). AR-12 demonstrates 
hMDM cytotoxicity at a concentration ≥ 10µM.
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AR-12 does not exert direct killing against S. Typhi in vitro and in the macrophages. (A) 
Growth curve of S. Typhi for the indicated concentrations of AR-12. (B) S. Typhi does not 
co-localize with MPs in hMDMs post-infection. Green = S. Typhi expressing GFP; Red = 
DTP/MPs; Blue = nuclei stained with DAPI. The results are representative of two 
experiments.
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AR-12 increases the co-localization of intracellular S. Typhi with autophagosomes in 
hMDMs. Co-localization (white arrows) of S. Typhi with autophagosomes induced by 
AR-12/MPs at (A) 6 h and (B) 18 h post treatment. (C) Percentage of S.Typhi co-localized 
with autophagosomes at 6h and 18h post treatment compared with vehicle treat control. 
Nuclei were stained with DAPI (blue); labeled S. Typhi is red; and autophagosomes are 
green. The results are representative of three experiments and presented as the average ± SD 
(***P ≤ 0.001).
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